Trial · NCT06425341
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PartA：Change in mean log10 serum hepatitis B surface antigen levels from baseline at week 12 | Week 12 | |
| Primary | PartB：Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48 | Week 48 | |
| Primary | PartC：Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48 | Week 48 | |
| Primary | PartD：Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48 | Week 48 | |
| Secondary | Changes from baseline in mean log10 serum hepatitis B surface antigen levels | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects with at least one log10 decline from baseline in serum hepatitis B surface antigen | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects with serum hepatitis B surface antigen loss | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects with serum hepatitis B surface antigen seroconversion | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects with hepatitis B e-antigen loss | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects with serum hepatitis B e-antigen seroconversion | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects with virologic breakthrough | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects with drug resistance | Pre-specified time points up to 72 weeks | |
| Secondary | Proportion of subjects who meet the criteria for stopping NA therapy | From 48 weeks to 72 weeks | |
| Secondary | Proportion of subjects with serum hepatitis B surface antigen loss and HBV DNA loss | Week 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06425341/registered